European Medicine's agency gives a negative opinion for fampridine:
"The Committee adopted a negative opinion recommending that fampridine, from Biogen-Idec Ltd, should not be granted a marketing authorisation. Fampyra was intended to be used to improve the walking ability of adult patients with multiple sclerosis."
Where to next?
Click here for EMA notification